REGENXBIO director granted RSUs and options
REGENXBIO Inc. director Argeris N. Karabelas received new equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
REGENXBIO Inc. director Argeris N. Karabelas received new equity awards as part of his compensation. He was granted 9,807 shares of common stock through a time-based restricted stock unit award that will fully vest on May 29, 2027, provided he continues to serve the company.
He also received stock options for 46,600 shares of common stock at an exercise price of $7.01 per share. These options begin vesting in 12 equal monthly installments after May 29, 2027 and expire on May 29, 2036. Following the RSU grant, he directly owns 28,861 shares of REGENXBIO common stock.
Insider Trade Summary
Grant/Award: 56,407 shares
Grant/Award
2 txns
Insider
KARABELAS ARGERIS N
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 46,600 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 9,807 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 46,600 contracts (Direct);
Common Stock — 28,861 shares (Direct)
Footnotes (2)
- F1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
- F2. The option will vest in 12 equal monthly installments following May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Key Figures
RSU grant size: 9,807 shares
Options granted: 46,600 options
Option exercise price: $7.01 per share
+3 more
6 metrics
RSU grant size
9,807 shares
Time-based RSU award vesting on May 29, 2027
Options granted
46,600 options
Stock Options (Right to Buy) granted May 29, 2026
Option exercise price
$7.01 per share
Conversion or exercise price for 46,600 stock options
Options expiration
May 29, 2036
Expiration date of granted stock options
Shares owned after RSU grant
28,861 shares
Total common stock directly held following the non-derivative acquisition
RSU vesting date
May 29, 2027
100% of RSU shares vest on this date, subject to service
Key Terms
restricted stock unit, Stock Options (Right to Buy), exercise price, vesting, +1 more
5 terms
restricted stock unit financial
"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Options (Right to Buy) financial
"security_title": "Stock Options (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "7.0100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the shares subject to this RSU will vest on May 29, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the continuous service of the recipient to the Issuer."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did REGENXBIO (RGNX) director Argeris Karabelas report?
Argeris N. Karabelas reported receiving equity compensation awards from REGENXBIO. He was granted 9,807 restricted stock units and stock options for 46,600 shares, both tied to continued service, with future vesting and no open-market buying or selling involved.
How many REGENXBIO (RGNX) RSUs did director Argeris Karabelas receive?
He received 9,807 shares of REGENXBIO common stock through a restricted stock unit award. All these RSUs will vest on May 29, 2027, as long as he continues to provide uninterrupted service to the company through that vesting date.
What are the key terms of the REGENXBIO (RGNX) stock options granted to Argeris Karabelas?
He received stock options covering 46,600 shares of REGENXBIO common stock at a $7.01 exercise price. These options start vesting in 12 equal monthly installments after May 29, 2027, and remain exercisable until their expiration on May 29, 2036.
When do the REGENXBIO (RGNX) RSUs granted to Argeris Karabelas vest?
All 9,807 RSUs granted to Argeris N. Karabelas will vest on May 29, 2027. Vesting requires his continuous service to REGENXBIO through that date, making the award fully time-based rather than performance-based according to the disclosure.
Are the REGENXBIO (RGNX) insider awards to Argeris Karabelas linked to performance targets?
The awards described are time-based rather than performance-based. The RSUs vest 100% on May 29, 2027, and the options vest in 12 monthly installments after that date, in each case conditioned on his continued service to REGENXBIO.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates